A stabilized basic aqueous hydrogen peroxide composition is disclosed. The composition contains about 0.3 wt % to about 15 wt % of hydrogen peroxide; water; and a stabilizer system that contains about 10 ppm to about 1% of a stannate stabilizer; 10 ppm to about 1% of a phosphonic acid chelating agent or a mixture of phosphonic acid chelating agents; and 10 ppm to about 1% of an aromatic chelating agent or a mixture of aromatic chelating agents. The composition comprises less than about 10 ppm pyrophosphate, preferably no pyrophosphate; and has a pH greater than 7.0, preferably about 8.0 to about 10.5.
Stabilized thickened hydrogen peroxide containing compositions are disclosed. The compositions contain a stabilizer system made up of a stannate stabilizer, a phosphorus containing stabilizer or a mixture of phosphorus containing stabilizers; and an aromatic chelating agent or a mixture of aromatic chelating agents. The compositions are suitable for use as disinfectants, as cleaning agents, and in various personal care applications such as hair care and tooth whitening.
Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor alpha 2 beta 1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin alpha 2 beta 1 with IC(50)s in the low nanomolar range. The conformation of the macrocycles was found to be highly important for the activity, and an X-ray crystal structure was obtained to clarify this. Subsequent docking into the metal-ion-dependent adhesion site (MIDAS) of a beta 1 unit revealed a binding model indicating key binding features. Macrocycle 38 was selected for further in vitro and in vivo profiling.